Comparative Urine Proteomic Studies of Overactive Bladder in Humans

The objectives of the study are:

1. to improve the diagnosis of overactive bladder using a non-invasive technology (urine
proteomics) and

2. to study how potential urine biomarkers changes with overactive bladder symptoms after
patients have been treated with fesoterodine, an FDA approved drug for the treatment of
overactive bladder.

Inclusion Criteria:

For healthy volunteers the inclusion criteria are:

1. Females ≥ 18 years old

2. Not experiencing overactive bladder symptoms

3. Not experiencing frequency or urgency

For overactive bladder patients the inclusion criteria are

1. Females ≥ 18 years old

2. Overactive bladder symptoms for ≥ 3 months before screening ) Recurrent UTIS > 3/year

Exclusion Criteria:

For healthy volunteers the exclusion criteria are:

1. Overactive bladder symptoms, such as frequency and urgency

2. Intermittent/unstable use of bladder medications

3. Pregnant women or women unwilling to use contraceptives

4. Neurological conditions: stroke, MS, Parkinson's, spinal cord injury

5. Significant pelvic organ prolapsed (grade 3 or above based on physical exam)

6. Lower urinary tract surgery within past 6 months

7. Known history of IC or pain associated with OAB

8. Urinary retention requiring catheterization, indwelling catheter of Self-cath

9. Recurrent UTIS > 3/year

For overactive bladder patients the exclusion criteria are:

1. Contraindications to Fesoterodine use such as hypersensitivity, GI and urinary
retention, and Glaucoma

2. Intermittent/unstable use of bladder medications

3. Pregnant women or women unwilling to use contraceptives

4. Neurological conditions: stroke, MS, Parkinson's, spinal cord injury

5. Significant pelvic organ prolapsed (grade 3 or above based on physical exam)

6. Lower urinary tract surgery within past 6 months

7. Known history of IC or pain associated with OAB

8. Urinary retention requiring catheterization, indwelling catheter of Self-cath

9. Recurrent UTIS > 3/year

Deferral Criteria:

Treatment with OAB medications within 2 weeks before baseline visit. If patient is
currently on OAB medications the patient will be asked to stop OAB medication for 2 weeks
and return for baseline visit.